eprintid: 19354
rev_number: 42
eprint_status: archive
userid: 1589
dir: disk0/00/01/93/54
datestamp: 2015-11-25 14:28:26
lastmod: 2024-04-08 16:27:12
status_changed: 2015-11-25 14:28:26
type: article
metadata_visibility: show
creators_name: Jarius, Sven
creators_name: Paul, Friedemann
creators_name: Fechner, Kai
creators_name: Ruprecht, Klemens
creators_name: Kleiter, Ingo
creators_name: Franciotta, Diego
creators_name: Ringelstein, Marius
creators_name: Pache, Florence
creators_name: Aktas, Orhan
creators_name: Wildemann, Brigitte
title: Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate
subjects: ddc-540
subjects: ddc-570
subjects: ddc-610
divisions: i-911100
abstract: Background: Neuromyelitis optica (NMO, Devic syndrome) is associated with antibodies to aquaporin-4 (NMO-IgG/AQP4-Ab) in the majority of cases. NMO-IgG/AQP4-Ab seropositivity in patients with NMO and its spectrum disorders has important differential diagnostic, prognostic and therapeutic implications. So-called cell-based assays (CBA) are thought to provide the best AQP4-Ab detection rates.   Objective: To compare directly the AQP4-IgG detection rates of the currently most widely used commercial CBA, which employs cells transfected with a full-length (M1)-human AQP4 DNA in a fashion that allows leaky scanning (LS) and thus expression of M23-AQP4 in addition to M1-AQP, to that of a newly developed CBA from the same manufacturer employing cells transfected with human M23-AQP4-DNA.   Methods: Results from 368 serum samples that had been referred for routine AQP4-IgG determination and had been tested in parallel in the two assays were compared.   Results: Seventy-seven out of 368 samples (20.9%) were positive for NMO-IgG/AQP4-Ab in at least one assay. Of these, 73 (94.8%) were positive in both assays. A single sample (1.3%) was exclusively positive in the novel assay; three samples (3.9%) were unequivocally positive only in the ‘classic’ assay due to high background intensity in the novel assay. Both median fluorescence intensity and background intensity were higher in the new assay.   Conclusions: This large study did not reveal significant differences in AQP4-IgG detection rates between the ‘classic’ CBA and a new M23-DNA-based CBA. Importantly, our results largely re-affirm the validity of previous studies that had used the ‘classic’ AQP4-CBA to establish NMO-IgG/AQP4-Ab seropositivity rates in NMO and in a variety of NMO spectrum disorders.  
date: 2014
publisher: BioMed Central
id_scheme: DOI
ppn_swb: 1653509686
own_urn: urn:nbn:de:bsz:16-heidok-193548
language: eng
bibsort: JARIUSSVENAQUAPORIN42014
full_text_status: public
publication: Journal of neuroinflammation: JNI
volume: 11
number: 129
place_of_pub: London
pagerange: 1-7
issn: 1742-2094
citation:   Jarius, Sven ; Paul, Friedemann ; Fechner, Kai ; Ruprecht, Klemens ; Kleiter, Ingo ; Franciotta, Diego ; Ringelstein, Marius ; Pache, Florence ; Aktas, Orhan ; Wildemann, Brigitte  (2014) Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate.  Journal of neuroinflammation: JNI, 11 (129).  pp. 1-7.  ISSN 1742-2094     
document_url: https://archiv.ub.uni-heidelberg.de/volltextserver/19354/1/12974_2014_Article_1041.pdf